tbuckley/cabot-search huggingface dataset:
Beyond median overall survival: Estimating multiple survival scenarios in patients with metastatic esophagogastric cancer.
Authors: Marieke Pape, Steven Kuijper, Pauline A.J. Vissers, Geert-Jan Creemers, Hanneke W.M. Van Laarhoven, Rob Verhoeven
Journal: Journal of Clinical Oncology (2022)

261 Background: Recent clinical trials of novel systemic therapies showed improved survival of patients with metastatic esophageal cancer (EC) and gastric cancer (GC). Survival improvements observed in clinical trials might be unrepresentative for the total population as the percentage of patients whom participate in clinical trials is limited and more than half of all patients receive best supportive care (BSC). The aim of our study is to assess the best-case, typical and worst-case survival scenarios in patients with metastatic esophagogastric cancer. Methods: We selected patients with metastatic EC (including junction) or GC diagnosed in 2006-2019 from the Netherlands Cancer Registry. Survival scenarios were calculated based on percentiles of the survival curve stratified by tumor location and treatment (tumor-directed therapy or BSC). Survival scenarios were calculated for the 10th (best-case), 25th (upper-typical), 75th (lower-typical) and 90th (worst-case) percentiles. Linear trend analysis was performed to test if changes in survival over the diagnosis years were significant. Results: We identified 12739 patients with EC and 6833 patients with GC. Percentage of patients receiving tumor-directed therapy increased from 34% to 47% and 30% to 45% for patients with EC and GC, respectively. The median survival remained unchanged for patients with EC (5.0 months) and improved slightly for patients with GC (3.1 to 3.7 months; P=0.006). For patients with EC survival of the best-case scenario improved (17.4 to 22.8 months; P=0.001), whereas the other scenarios remained unchanged: upper-typical 11.2 to 11.7 (P=0.11), lower-typical 2.1 to 2.0 (P=0.10) and worst-case 0.9 to 0.8 months (P=0.22). For patients with GC survival improved for the best-case (13.1 to 19.5; P=0.005) and upper-typical scenario (6.7 to 10.6 months; P=0.002), whereas the lower-typical (1.2 to 1.4 months; P=0.87) and worst-case (0.6 to 0.6 months; P=0.60) remained unchanged. For patients with EC receiving tumor-directed therapy survival in all scenarios remained unchanged while for patients receiving BSC survival decreased: best-case 11.8 to 9.8 (P=0.005), upper-typical 6.0 to 5.0 (P=0.002), lower-typical 1.4 to 1.0 (P=0.003) and worst-case 0.7 to 0.5 months (P=0.03). For patients with GC receiving tumor-directed therapy survival improved for all scenarios: best-case 19.8 to 30.4 (P=0.005), upper-typical 6.4 to 10.3 (P=0.002), lower-typical 3.6 to 5.4 (P&lt;0.001) and worst-case 1.4 to 2.6 months (P&lt;0.001), and for patients receiving BSC survival for all scenarios remained unchanged. Conclusions: The proportion of patients with EC and GC receiving tumor-directed therapy increased over time. Despite the fact that survival improvements were not observed across all scenarios, at least an increase in survival was observed in certain subgroups of patients.
Conivaptan (Cl-1025, YM087), a combined vasopressin V1A/V2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients William B. Smith, Stuart Russell, Jalal K. Ghali, Christopher A. Painchaud, Paulina Selaru, Maha M. Ghazzi, Marvin A. Konstam, James E. Udelson. New Orleans Center for Clinical Research, New Orleans, LA, Duke University, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
NATIONAL CANCER INSTITUTE MONOGRAPHS
Journal: JNCI Journal of the National Cancer Institute (1988)

NATIONAL CANCER INSTITUTE MONOGRAPHS JNCI: Journal of the National Cancer Institute, Volume 80, Issue 18, 16 November 1988, Page 1509, https://doi.org/10.1093/jnci/80.18.1509 Published: 16 November 1988
Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching
Authors: John M. Burke, Nicholas Liu, Kristina Yu-Isenberg, Michelle A. Fanale, Andy Surinach, Carlos Flores, Julie Lisano, Tycel J. Phillips
Journal: Blood (2020)
Efficacy and implantation rates of implantable cardioverter defibrillators in Olmsted County, Minnesota: 1989?1999 Lambert A. Wu, Thomas E. Kottke, Paul A. Friedman, David M. Luria, Diane E. Grill, Matthew J. Maurer. Mayo Clinic, Rochester, MN
Journal: Journal of the American College of Cardiology (2001)
Venous Obstruction of Upper Extremity Caused by Malformed Valve of Subclavian Vein
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Travelling with heart failure: risk assessment and practical recommendations
Authors: Stephan von Haehling, Christoph Birner, Elke Dworatzek, Stefan Frantz, Kristian Hellenkamp, Carsten W. Israel, Tibor Kempf, Hermann H. Klein, Christoph Knosalla, Ulrich Laufs, Philip Raake, Rolf Wachter, Gerd Hasenfuss
Journal: Nature Reviews Cardiology (2022)
Global HIV efforts need to focus on key populations in LMICs
Authors: Leickness C Simbayi, Sizulu Moyo, Alastair van Heerden, Khangelani Zuma, Nompumelelo Zungu, Edmore Marinda, Sean Edwin Jooste, Allanise Cloete, Musawenkosi Mabaso, Heidi van Rooyen
Journal: The Lancet (2021)
SELENIUM PROBLEM
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association News
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tetracycline and staining of the teeth
Authors: E. R. Grossman
Journal: JAMA (1986)

<h3>In Reply.—</h3> We appreciate Dr Grossman's interest in our article. He objects to our statement concerning tetracycline's ability to stain teeth only when administered before the age of 7 years. This information was derived from<i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i>.<sup>1</sup>In addition, the package insert for each tetracycline preparation, as listed in the<i>Physicians' Desk Reference</i>,<sup>2</sup>contains a warning concerning its use "up to the age of 8 years." Another source<sup>3</sup>agrees with this age and adds that "the stains resulting from tetracycline exposure during this period may not become visible for several years." We do not know whether Dr Grossman is correct in his opinion that "tetracycline... will continue to bind to the relatively unseen posterior teeth... until they have completed calcifying, years later." It is unfortunate that this speculation is not substantiated with data in either his letter or references. He states
<i>European Respiratory Journal</i>, list of peer reviewers 2019
Journal: European Respiratory Journal (2020)

<h3>Objective:</h3> To investigate the role of known multiple sclerosis (MS)-associated genetic variants in MS familial aggregation, clinical expression, and accuracy of disease prediction in sporadic and familial cases. <h3>Methods:</h3> A total of 1,443 consecutive patients were screened for MS and familial autoimmune history in a hospital-based Italian cohort. Among them, 461 sporadic and 93 familial probands were genotyped for 107 MS-associated polymorphisms. Their effect sizes were combined to calculate the weighted genetic risk score (wGRS). <h3>Results:</h3> Family history of MS was reported by 17.2% of probands, and 33.8% reported a familial autoimmune disorder, with autoimmune thyroiditis and psoriasis being the most frequent. No difference in wGRS was observed between sporadic and familial MS cases. In contrast, a lower wGRS was observed in probands with greater familial aggregation (&gt;1 first-degree relative or &gt;2 relatives with MS) (<i>p</i> = 0.03). Also, female probands of familial cases with greater familial aggregation had a lower wGRS than sporadic cases (<i>p</i> = 0.0009) and male probands of familial cases (<i>p</i> = 0.04). An inverse correlation between wGRS and age at onset was observed (<i>p</i> = 0.05). The predictive performance of the genetic model including all known MS variants was modest but greater in sporadic vs familial cases (area under the curve = 0.63 and 0.57). <h3>Conclusions:</h3> Additional variants outside the known MS-associated loci, rare variants, and/or environmental factors may explain disease occurrence within families; in females, hormonal and epigenetic factors probably have a predominant role in explaining familial aggregation. The inclusion of these additional factors in future versions of aggregated genetic measures could improve their predictive ability.
Can exercise training teach us how to treat Alzheimer’s disease?
Authors: Aleksi M. Huuha, Cecilie S. Norevik, José Bianco N. Moreira, Asgeir Kobro-Flatmoen, Nathan Scrimgeour, Miia Kivipelto, Henriette Van Praag, Maryam Ziaei, Sigrid Botne Sando, Ulrik Wisløff, Atefe R. Tari
Journal: Ageing Research Reviews (2022)

Alzheimer's disease (AD) is the most common cause of dementia and there is currently no cure. Novel approaches to treat AD and curb the rapidly increasing worldwide prevalence and costs of dementia are needed. Physical inactivity is a significant modifiable risk factor for AD, estimated to contribute to 12.7% of AD cases worldwide. Exercise interventions in humans and animals have shown beneficial effects of exercise on brain plasticity and cognitive functions. In animal studies, exercise also improved AD pathology. The mechanisms underlying these effects of exercise seem to be associated mainly with exercise performance or cardiorespiratory fitness. In addition, exercise-induced molecules of peripheral origin seem to play an important role. Since exercise affects the whole body, there likely is no single therapeutic target that could mimic all the benefits of exercise. However, systemic strategies may be a viable means to convey broad therapeutic effects in AD patients. Here, we review the potential of physical activity and exercise training in AD prevention and treatment, shining light on recently discovered underlying mechanisms and concluding with a view on future development of exercise-free treatment strategies for AD.
Air
Authors: Lynette Lamp
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Age-related trends in the incidence of metastatic colorectal cancer over the last 10 years: A retrospective analysis in commercially-insured population in the United States.
Authors: Zdravko Vassilev, Helen Guo, Wenlong Lin, Julie Xu, Nasreen Khan
Journal: Journal of Clinical Oncology (2022)

46 Background: Previous studies have suggested age-related shifts in the incidence of metastatic colorectal cancer (mCRC). However, more contemporary data is needed to further understand the continuous changes in the distribution of mCRC and patient characteristics across different age groups. Methods: A retrospective observational study was conducted using the Optum Clinformatics database to estimate the incidence rates (IRs) and temporal trends of newly diagnosed mCRC during 2010-2019, stratified by age categories (18-49; 50-64; and 65+). IRs were calculated as the actual patient number of newly diagnosed mCRC divided by the overall enrollment number. The IRs were standardized to the 2010 US population and trends over time were characterized using annual percentage changes (APCs). Results: Total of 23,970 newly diagnosed patients with mCRC were identified during 2010-2019. Median age was 71 years, 65% of patients were white, and 68% of patients had commercial Medicare insurance. Most patients (69%) were 65 years of age or older at the time of mCRC diagnosis. Patients characteristics were similar across age groups, except for race and geographic region. The proportion of Hispanic (12.6%) and Asian (4.7%) mCRC patients was higher in the younger 18-49 group than in the 50-64 (respectively 9.4% and 3%) and 65+ groups (respectively 9.5% and 2.9%). Higher proportions in the 18-49 (44.4%) and 50-64 (47.5%) groups than in the 65+ group (37.6%) were from the South, while higher proportions in the 65+ group were from the West and Northeast (24.4% and 14%). Standardized IRs of mCRC decreased by 22% from 64.4 in 2010 to 50.5 per 100,000 in 2019 among patients 65+, with an APC of -2,11. Standardized IRs increased over the same period by 15% in the 50-64 group, APC = 2.33 and by 22% in the 18-49 age group, APC = 2.8. Conclusions: Temporal changes in mCRC incidence in a large commercially insured population during 2010-2019, showed an increasing trend in younger patients and a decreasing trend in patients 65+. The highest increase in IRs from 2010 to 2019 occurred in the 18-49 age group. Hispanic and Asian patients were more present among the 18-49 than among the older patient groups, and there were geographic differences among the age groups. The changes in age- distribution and evolving patient characteristics need to be considered in the delivery of treatments and care for mCRC.
Minimal coronary artery disease is associated with persistent chest pain in women: Results from the NHLBI-sponsored WISE study coronary angiographic core laboratory Barry L. Sharaf, B. Delia Johnson, Marian B. Olson, Carl J. Pepine, Steven E. Reis, William J. Rogers, Nathaniel Reichek, C. Noel Bairey Merz. Rhode Island Hospital and Brown University School of Medicine, Providence, RI
Journal: Journal of the American College of Cardiology (2001)
Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents
Authors: Jian Yu, Xin Chen, Yuanjin Zhang, Xiangdi Cui, Zhe Zhang, Wenxiu Guo, Dongmei Wang, Shengbo Huang, Yanru Chen, Yepeng Hu, Cheng Zhao, Jin Qiu, Yu Li, Meiyao Meng, Mingwei Guo, Fei Shen, Mengdi Zhang, Ben Zhou, Xuejiang Gu, Jiqiu Wang, Xin Wang, Xinran Ma, Lingyan Xu
Journal: Theranostics (2022)

Obesity, a metabolic disease caused by multiple factors, has become a global health problem.In addition to nutrient intake and sedentary lifestyle, environmental pollutants exposure has been shown to be involved in obesity epidemics.Antibiotics, a new type of environmental pollutant, have been widely used in animal husbandry, aquaculture and microorganism.However, the effects of antibiotics exposure on fat metabolism and metabolic diseases are largely unknown.Methods: We screened major types of antibiotics to examine their effects on the differentiation capacity and thermogenic functionality of brown and beige adipocytes, and found that azithromycin, one major kind of macrolide antibiotics suppressed brown and beige adipocyte functionality.We thus examined azithromycin accretion in adipose tissues of obese patients that correlates with BMI by high performance liquid chromatography-tandem mass spectrometry and systematically explore the influences of azithromycin on adiposity and metabolic performance in mice under high diet.Results: Azithromycin (macrolides) inhibits the mitochondrial and thermogenic gene programs of brown and beige adipocytes, thus disrupting their mitochondrial function and thermogenic response.Consistently, azithromycin treatment are more prone to diet-induced obesity in mice, and this was associated with impaired energy expenditure.Importantly, azithromycin is more accumulated in adipose tissue of obese patients and correlates with BMI and body weight.Mechanistically, we found that azithromycin inhibits mitochondria respiratory complex I protein levels and increases reactive oxidative species (ROS) levels, which causes damage of mitochondrial function in brown and beige adipocytes.The deleterious effects of azithromycin can be ameliorated by antioxidant N-acetyl-L-cysteine. Conclusions: Taken together, this work highlights the possible role of azithromycin in obesity epidemic and presents strategies for safe applications of antibiotics in the future.
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification
Authors: Jennifer L. Sauter, Sanja Dacic, Francoise Galateau-Salle, Richard L. Attanoos, Kelly J. Butnor, Andrew Churg, Aliya N. Husain, Kyuichi Kadota, Andras Khoor, Andrew G. Nicholson, Victor Roggli, Fernando Schmitt, Ming-Sound Tsao, William D. Travis
Journal: Journal of Thoracic Oncology (2022)
A medical team goes to Olympics
Authors: P. Gunby
Journal: JAMA (1984)

Members.LTAembers of one of the best-trained American teams in Los Angeles are hoping not to see much action during the forthcoming summer Olympic Games. They are physicians of the Epidemic Intelligence Service, which has its headquarters at the Centers for Disease Control (CDC), Atlanta (<i>JAMA</i>[MEDICAL NEWS] 1979;241:2776-2782 and 1983;250:1131-1132). From now until Aug 12, when the 23rd Olympiad is scheduled to end, they are joining other public health officials in watching for what Michael B. Gregg, MD, calls "big or puzzling" changes in the health status of the hundreds of thousands of people on hand for the summer Games. Gregg, deputy director of the CDC's Epidemiology Program Office and editor of the<i>Morbidity and Mortality Weekly Report</i>, says the surveillance is being carried out in close cooperation with state and local health officials and that a key ingredient is "a first-rate communications system." Physicians of the Epidemic Intelligence Service—usually
INDIA
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infectious disease surveillance update
Authors: Pam Das
Journal: The Lancet Infectious Diseases (2004)

Laboratory tests have confirmed that the Côte ďIvoire has become the eighth polio-free African country to be re-infected from Nigeria. Its last polio case was reported in July 2000. The Northern states of Kano have not resumed immunisation as hoped by the donor organisations as the safety issues surrounding the vaccine have still not been resolved. Rumours that Nigeria will procure their vaccines from elsewhere are unfounded. David Heymann (WHO) told TLID, "Nigeria have a contract with Unicef to get their vaccines, which come from various companies around the world.